Merck and Quotient Therapeutics Partner to Discover New IBD Drug Targets

Quotient Therapeutics has announced a multi-year research collaboration with Merck, known as MSD outside the US and Canada. The strategic partnership aims to identify novel therapeutic targets for inflammatory bowel disease (IBD) through advanced genomic research. Under the agreement, the companies will leverage Quotient's proprietary somatic genomics platform technology to study genetic variations within tissues. This collaboration seeks to uncover breakthrough medicines by analyzing how somatic mutations contribute to disease progression. For Merck, the deal strengthens its long-term drug discovery pipeline in the immunology space. The partnership underscores the growing importance of genomics-driven platforms in modern biotechnology and pharmaceutical development.

Sources:globenewswire.comstocktitan.netenfarma.latthailandmedical.newsmarketscreener.comfiercebiotech.combizjournals.comfirstwordpharma.com